Long-term Survival with Ipilimumab: Experience from a National
Expanded Access Program for Patients with Melanoma

J 2015

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma

KRAJSOVÁ, Ivana; Petr ARENBERGER; Radek LAKOMÝ; Eugen KUBALA; Ivana BŘEZINOVÁ et. al.

Základní údaje

Originální název

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma

Autoři

KRAJSOVÁ, Ivana (203 Česká republika); Petr ARENBERGER (203 Česká republika); Radek LAKOMÝ (203 Česká republika); Eugen KUBALA (203 Česká republika); Ivana BŘEZINOVÁ (203 Česká republika); Alexandr POPRACH (203 Česká republika); Marek ŠŤASTNÝ (203 Česká republika); Jan MUŽÍK (203 Česká republika, garant, domácí) a Bohuslav MELICHAR (203 Česká republika)

Vydání

Anticancer Research, Athens, The International Institute of Anticancer Research, 2015, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.895

Kód RIV

RIV/00216224:14110/15:00085108

Organizační jednotka

Lékařská fakulta

UT WoS

000363794900075

Klíčová slova anglicky

Melanoma; ipilimumab; survival; safety

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 12. 2015 16:05, Soňa Böhmová

Anotace

V originále

Aim: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. Patients and Methods: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. Results: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p<0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS. Conclusion: The number of affected organs and combination of baseline LDH and CRP levels could potentially serve as predictors for both treatment response and OS.

Citovat

KRAJSOVÁ, Ivana; Petr ARENBERGER; Radek LAKOMÝ; Eugen KUBALA; Ivana BŘEZINOVÁ; Alexandr POPRACH; Marek ŠŤASTNÝ; Jan MUŽÍK a Bohuslav MELICHAR. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. Anticancer Research. Athens: The International Institute of Anticancer Research, 2015, roč. 35, č. 11, s. 6303-6310. ISSN 0250-7005.

@article{1320374,
   author = {Krajsová, Ivana and Arenberger, Petr and Lakomý, Radek and Kubala, Eugen and Březinová, Ivana and Poprach, Alexandr and Šťastný, Marek and Mužík, Jan and Melichar, Bohuslav},
   article_location = {Athens},
   article_number = {11},
   keywords = {Melanoma; ipilimumab; survival; safety},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma},
   volume = {35},
   year = {2015}
}

TY  - JOUR
ID  - 1320374
AU  - Krajsová, Ivana - Arenberger, Petr - Lakomý, Radek - Kubala, Eugen - Březinová, Ivana - Poprach, Alexandr - Šťastný, Marek - Mužík, Jan - Melichar, Bohuslav
PY  - 2015
TI  - Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
JF  - Anticancer Research
VL  - 35
IS  - 11
SP  - 6303-6310
EP  - 6303-6310
PB  - The International Institute of Anticancer Research
SN  - 02507005
KW  - Melanoma
KW  - ipilimumab
KW  - survival
KW  - safety
N2  - Aim: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. Patients and Methods: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. Results: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p<0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS. Conclusion: The number of affected organs and combination of baseline LDH and CRP levels could potentially serve as predictors for both treatment response and OS.
ER  -

KRAJSOVÁ, Ivana; Petr ARENBERGER; Radek LAKOMÝ; Eugen KUBALA; Ivana BŘEZINOVÁ; Alexandr POPRACH; Marek ŠŤASTNÝ; Jan MUŽÍK a Bohuslav MELICHAR. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. \textit{Anticancer Research}. Athens: The International Institute of Anticancer Research, 2015, roč.~35, č.~11, s.~6303-6310. ISSN~0250-7005.

Přehled o publikaci